Evgeni Dvortsin Judith Gout-Zwart Ernst-Lodewijk Marie Eijssen Jan van Brussel Maarten J Postma
10.1371/journal.pone.0146551
PLoS One
2016 Jan 22;11(1):e0146551.
CC BY
https://pubmed.ncbi.nlm.nih.gov/26800029/
Antineoplastic Agents / economics Antineoplastic Agents / therapeutic use Breast Neoplasms / drug therapy Cost-Benefit Analysis Insurance, Health, Reimbursement / economics Insurance, Pharmaceutical Services / economics
Antineoplastic Agents / economics Antineoplastic Agents / therapeutic use Breast Neoplasms / drug therapy Cost-Benefit Analysis Insurance, Health, Reimbursement / economics Insurance, Pharmaceutical Services / economics Case Reports Research Support, Non-U.S. Gov't Review Aniline Compounds / economics Aniline Compounds / therapeutic use Bortezomib / economics Bortezomib / therapeutic use Breast Neoplasms / mortality Cetuximab / economics Cetuximab / therapeutic use Female Humans Middle Aged Neoplasm Staging Netherlands Nitriles / economics Nitriles / therapeutic use Quality-Adjusted Life Years Quinolines / economics Quinolines / therapeutic use Scotland Trastuzumab / economics Trastuzumab / therapeutic use Aniline Compounds Antineoplastic Agents Nitriles Quinolines bosutinib Bortezomib Trastuzumab Cetuximab
PMC4723090
26800029
Comparative Cost-Effectiveness of Drugs in Early versus Late Stages of Cancer; Review of the Literature and a Case Study in Breast Cancer
2016